iBio, Inc. (IBIO): Price and Financial Metrics


iBio, Inc. (IBIO): $0.17

-0.01 (-6.53%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IBIO to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

IBIO Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for IBIO is 0.04 -- better than only 10.03% of US stocks.
  • With a price/sales ratio of 24.82, IBIO INC has a higher such ratio than 94.89% of stocks in our set.
  • Revenue growth over the past 12 months for IBIO INC comes in at -6.23%, a number that bests only 15.96% of the US stocks we're tracking.
  • Stocks that are quantitatively similar to IBIO, based on their financial statements, market capitalization, and price volatility, are SCWX, CTSO, ATEN, VTEX, and DIOD.
  • Visit IBIO's SEC page to see the company's official filings. To visit the company's web site, go to www.ibioinc.com.

IBIO Valuation Summary

  • In comparison to the median Healthcare stock, IBIO's price/earnings ratio is 111.73% lower, now standing at -2.3.
  • IBIO's EV/EBIT ratio has moved up 6.4 over the prior 156 months.

Below are key valuation metrics over time for IBIO.

Stock Date P/S P/B P/E EV/EBIT
IBIO 2022-09-23 26.7 0.9 -2.3 -2.0
IBIO 2022-09-22 28.7 1.0 -2.4 -2.2
IBIO 2022-09-21 29.5 1.0 -2.5 -2.3
IBIO 2022-09-20 26.4 0.9 -2.2 -2.0
IBIO 2022-09-19 29.5 1.0 -2.5 -2.3
IBIO 2022-09-16 35.7 1.3 -3.0 -2.8

IBIO Growth Metrics

    Its year over year net income to common stockholders growth rate is now at -22.73%.
  • Its 2 year net cashflow from operations growth rate is now at -139.39%.
  • The 2 year cash and equivalents growth rate now stands at 295.5%.
Over the past 15 months, IBIO's revenue has gone up $482,000.

The table below shows IBIO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-03-31 2.813 -33.203 -33.286
2021-12-31 1.635 -34.608 -28.621
2021-09-30 2.172 -32.341 -24.873
2021-06-30 2.371 -30.064 -23.467
2021-03-31 3 -26.705 -27.121
2020-12-31 2.331 -23.142 -24.137

IBIO's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • IBIO has a Quality Grade of D, ranking ahead of 5.38% of graded US stocks.
  • IBIO's asset turnover comes in at 0.017 -- ranking 375th of 681 Pharmaceutical Products stocks.
  • COLL, COCP, and IRWD are the stocks whose asset turnover ratios are most correlated with IBIO.

The table below shows IBIO's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.017 0.383 -0.256
2021-03-31 0.024 0.836 -0.331
2020-12-31 0.023 1.000 -0.317
2020-09-30 0.027 1.000 -0.273
2020-06-30 0.032 1.000 -0.231
2020-03-31 0.036 1.000 -0.271

IBIO Stock Price Chart Interactive Chart >

Price chart for IBIO

IBIO Price/Volume Stats

Current price $0.17 52-week high $1.07
Prev. close $0.18 52-week low $0.17
Day low $0.17 Volume 3,564,636
Day high $0.19 Avg. volume 2,403,633
50-day MA $0.28 Dividend yield N/A
200-day MA $0.35 Market Cap 37.15M

iBio, Inc. (IBIO) Company Bio


iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. Its pipeline include idiopathic pulmonary fibrosis, systemic sclerosis, and scleroderma. It operates through the iBio, Inc. and iBio CDMO business segments. The company was founded on April 15, 1993 and is headquartered in New York, NY.


IBIO Latest News Stream


Event/Time News Detail
Loading, please wait...

IBIO Latest Social Stream


Loading social stream, please wait...

View Full IBIO Social Stream

Latest IBIO News From Around the Web

Below are the latest news stories about IBIO INC that investors may wish to consider to help them evaluate IBIO as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

It's time for another dive into the biggest pre-market stock movers as we check out what's going on on Wednesday morning.

William White on InvestorPlace | September 28, 2022

Edited Transcript of IBIO.A earnings conference call or presentation 27-Sep-22 8:30pm GMT

Q4 2022 Ibio Inc Earnings Call

Yahoo | September 27, 2022

iBio Reports Preliminary Unaudited Fiscal Year 2022 Financial Results and Provides Corporate Update

BRYAN, Texas and SAN DIEGO, Sept. 27, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today announces preliminary unaudited financial results for the fiscal year ended June 30, 2022, and provides a corporate update. “We have continued to take important steps toward achieving our strategic objective of becoming a leading biotechnology company with a focu

Yahoo | September 27, 2022

iBio Acquires RubrYc Therapeutics’ AI Drug Discovery Platform and Pipeline

– Positions Company for leadership in AI-powered drug discovery – – Expands iBio’s immuno-oncology pipeline with three new candidates – – Hosting investor call on September 27th to discuss transaction, the Company’s transformation and FY2022 financial results – SAN DIEGO and BRYAN, Texas, Sept. 21, 2022 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), a developer of next-generation biopharmaceuticals and pioneer of the sustainable FastPharming® Manufacturing System, today a

Yahoo | September 21, 2022

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday

We're starting off the week with a breakdown of the biggest pre-market stock movers for Monday morning and the news behind them!

William White on InvestorPlace | September 19, 2022

Read More 'IBIO' Stories Here

IBIO Price Returns

1-mo -38.69%
3-mo -34.62%
6-mo -60.66%
1-year -83.96%
3-year -68.38%
5-year -94.69%
YTD -69.03%
2021 -47.71%
2020 321.69%
2019 -66.80%
2018 -57.63%
2017 -55.75%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5842 seconds.